Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study.
Saved in:
| Title: | Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study. |
|---|---|
| Authors: | Peeters SLJ; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands., Heersche N; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands., Böhm D; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands., Böhringer S; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, Netherlands., Guiljam R; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands., Hulshof EC; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands., de Man FM; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands., de With M; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands., Joosse M; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., Oomens G; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., Wu QY; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands., Osman A; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands., Bins S; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands., van Hellemond IEG; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Haberkorn BCM; Department of Medical Oncology, Maasstad Hospital, Rotterdam, the Netherlands., Verschoor AJ; Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, the Netherlands., Wumkes ML; Department of Medical Oncology, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands., van Schaik RHN; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands., Thijs AM; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands., Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands., Mathijssen RHJ; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands., Deenen MJ; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands. |
| Source: | The Lancet regional health. Europe [Lancet Reg Health Eur] 2026 Feb 23; Vol. 64, pp. 101629. Date of Electronic Publication: 2026 Feb 23 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: [Oxford] Country of Publication: England NLM ID: 101777707 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-7762 (Electronic) Linking ISSN: 26667762 NLM ISO Abbreviation: Lancet Reg Health Eur Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41777427 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Peeters+SLJ%22">Peeters SLJ</searchLink>; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Heersche+N%22">Heersche N</searchLink>; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Böhm+D%22">Böhm D</searchLink>; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Böhringer+S%22">Böhringer S</searchLink>; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, Netherlands.<br /><searchLink fieldCode="AU" term="%22Guiljam+R%22">Guiljam R</searchLink>; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Hulshof+EC%22">Hulshof EC</searchLink>; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Man+FM%22">de Man FM</searchLink>; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22de+With+M%22">de With M</searchLink>; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Joosse+M%22">Joosse M</searchLink>; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Oomens+G%22">Oomens G</searchLink>; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Wu+QY%22">Wu QY</searchLink>; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Osman+A%22">Osman A</searchLink>; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Bins+S%22">Bins S</searchLink>; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Hellemond+IEG%22">van Hellemond IEG</searchLink>; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Haberkorn+BCM%22">Haberkorn BCM</searchLink>; Department of Medical Oncology, Maasstad Hospital, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Verschoor+AJ%22">Verschoor AJ</searchLink>; Department of Medical Oncology, Reinier de Graaf Gasthuis, Delft, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Wumkes+ML%22">Wumkes ML</searchLink>; Department of Medical Oncology, Jeroen Bosch Hospital, 's Hertogenbosch, the Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Schaik+RHN%22">van Schaik RHN</searchLink>; Department of Clinical Chemistry, Erasmus University Medical Centre, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Thijs+AM%22">Thijs AM</searchLink>; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Gelderblom+H%22">Gelderblom H</searchLink>; Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Guchelaar+HJ%22">Guchelaar HJ</searchLink>; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Mathijssen+RHJ%22">Mathijssen RHJ</searchLink>; Department of Medical Oncology, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Deenen+MJ%22">Deenen MJ</searchLink>; Department of Clinical Pharmacy, Catharina Hospital, Eindhoven, the Netherlands.; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre Leiden, the Netherlands. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101777707%22">The Lancet regional health. Europe</searchLink> [Lancet Reg Health Eur] 2026 Feb 23; Vol. 64, pp. 101629. <i>Date of Electronic Publication: </i>2026 Feb 23 (<i>Print Publication: </i>2026). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22[Oxford]%22">[Oxford] </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101777707 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2666-7762 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2226667762%22">26667762 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Reg Health Eur <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41777427 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.lanepe.2026.101629 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 101629 Titles: – TitleFull: Survival of patients with colorectal or pancreatic cancer who received UGT1A1 genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Peeters SLJ – PersonEntity: Name: NameFull: Heersche N – PersonEntity: Name: NameFull: Böhm D – PersonEntity: Name: NameFull: Böhringer S – PersonEntity: Name: NameFull: Guiljam R – PersonEntity: Name: NameFull: Hulshof EC – PersonEntity: Name: NameFull: de Man FM – PersonEntity: Name: NameFull: de With M – PersonEntity: Name: NameFull: Joosse M – PersonEntity: Name: NameFull: Oomens G – PersonEntity: Name: NameFull: Wu QY – PersonEntity: Name: NameFull: Osman A – PersonEntity: Name: NameFull: Bins S – PersonEntity: Name: NameFull: van Hellemond IEG – PersonEntity: Name: NameFull: Haberkorn BCM – PersonEntity: Name: NameFull: Verschoor AJ – PersonEntity: Name: NameFull: Wumkes ML – PersonEntity: Name: NameFull: van Schaik RHN – PersonEntity: Name: NameFull: Thijs AM – PersonEntity: Name: NameFull: Gelderblom H – PersonEntity: Name: NameFull: Guchelaar HJ – PersonEntity: Name: NameFull: Mathijssen RHJ – PersonEntity: Name: NameFull: Deenen MJ IsPartOfRelationships: – BibEntity: Dates: – D: 23 M: 02 Text: 2026 Feb 23 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2666-7762 Numbering: – Type: volume Value: 64 Titles: – TitleFull: The Lancet regional health. Europe Type: main |
| ResultId | 1 |
